Results 171 to 180 of about 115,890 (298)

Changing Faces of Heme Oxygenases

Antioxidants & Redox Signaling, 2007
openaire   +3 more sources

SIRT1 in Neurodegenerative Diseases: Molecular Mechanisms, Disease Relevance, and Therapeutic Potential

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
SIRT1, an NAD+‐dependent deacetylase, supports cognitive resilience by coordinating neuroprotection, synaptic plasticity, autophagy–lysosomal proteostasis, and mitochondrial energy homeostasis. Reduced or dysregulated SIRT1 is associated with protein aggregation, neuroinflammation, mitochondrial dysfunction, synaptic loss, and cognitive decline in ...
Jiabin Duan, Jiaqi Liu, Qingsheng Meng, Jiahao Liu, Sitian Yang, Fang Zhou, Jing Cao   +6 more
wiley   +1 more source

Physiological Occlusal Force Promotes Heme Oxygenase-1 to Repair Periodontal Injury in a Rat Model of Replanted Teeth. [PDF]

Int Dent J
Jia W, Liu X, Wu C, Wu C, Jiang L.
europepmc   +1 more source

Redox mechanisms of the beneficial effects of heme oxygenase in hypertension

, 2014
Heme oxygenases, namely heme oxygenase-1 and heme oxygenase-2, have important biological functions in vascular homeostasis. Heme oxygenase and its catabolic products, including bilirubin and carbon monoxide, have been implicated in blood pressure ...
Dusting, GJ (15629489), Jiang, F (15622742), Chan, EC (15663968), Guei-Sheung Liu (14742562)   +3 more
core  

Acute caffeine treatment protects the developing retina from ischemia‐induced cell death

FEBS Open Bio, Volume 16, Issue 9, Page 1726-1740, September 2026.
Caffeine reduces cell death in the developing retina under ischemia (OGD). This effect does not involve BDNF upregulation or antioxidant pathways (NRF2/VEGF). Neuroprotection occurs mainly through adenosine A2A receptor antagonism, decreasing glutamate release and excitotoxicity, highlighting caffeine's potential as an acute neuroprotective agent in ...
Amanda Alves Nascimento, Danniel Pereira‐Figueiredo, Gabriella Grossi de Lima Dias, Gabriel Ferreira dos Santos, Mariana Rodrigues Pereira, Rafael Brito, Karin C Calaza   +6 more
wiley   +1 more source

Biointegrated Battery‐Based Electroceuticals

Advanced Materials, Volume 38, Issue 52, 16 September 2026.
Biointegrated batteries go beyond passive power to serve as active therapeutic platforms for delivering programmable electrical cues and bioactive agents. This review examines their mechanisms and applications and provides a framework to guide battery‐based therapeutic design and clinical translation.
Yan Zhou, Zhilian Yue, Zhiqi Chen, Danming Chao, Xiaoteng Jia, Gordon Wallace, Caiyun Wang   +6 more
wiley   +1 more source

CMAH-Targeted Knock-In of Inducible Heme Oxygenase-1 and Constitutive CD47 in GGTA1-Knockout Pigs for Xenotransplantation. [PDF]

Xenotransplantation
Lee H, Kim SE, Lee WK, Oh M, Lee S, No JG, Park MR, Kim S, Do MH, Oh KB.   +9 more
europepmc   +1 more source

A Multifaceted Interplay Among Hemophagocytosis, Interleukin‐18, and Type I Interferon Distinguishes Still Disease From Other Autoinflammatory Diseases

Arthritis &Rheumatology, Volume 78, Issue 9, Page 1961-1974, September 2026.
Objective The unknown pathophysiology and the lack of specific features for systemic juvenile idiopathic arthritis and adult‐onset Still disease (collectively known as Still disease; SD) delay diagnosis and appropriate treatment. The goal of this study was to identify features and mechanisms that distinguish SD from other systemic autoinflammatory ...
Yvonne M. Mueller, Charlotte Girard, Harmen J. G. van de Werken, Stefan J. Erkeland, Dwin G. B. Grashof, Laurie Vaillant, Renske J. H. den Dekker, Iris van Zuijen, Sharon Veenbergen, Fanny Coffin, Eric Bindels, Yvan Jamilloux, Katerina Laskari, Vassili Soumelis, Bruno Fautrel, Cem Gabay, Peter D. Katsikis   +16 more
wiley   +1 more source

Crystal structure of RohS, a heme-oxygenase-like N-oxygenase from azomycin biosynthesis. [PDF]

J Biol Chem
Wei ZW, Salamon P, Higgins MA, Ryan KS.
europepmc   +1 more source

Natural Compounds Targeting Oncogenic Signaling Networks in Glioblastoma: Molecular Mechanisms, Translational Advances, and Clinical Perspectives

Brain and Behavior, Volume 16, Issue 9, September 2026.
Glioblastoma (GBM) is a highly aggressive brain tumor with a poor prognosis, driven by abnormal signaling pathways that promote growth and resistance to treatment. Conventional therapies are inadequate, highlighting the need for novel multitargeted approaches.
Mehrukh Zehravi, Md Abul Hassan, Md. Al Amin, Sherouk Hussein Sweilam, Jeetendra Kumar Gupta, Ramenani Hari Babu, Pericharla Venkata Narasimha Raju, Krishna Vamsi Kandimalla, Phanindra Erukulla, Patibandla Jahnavi, Rajeshwar Vodeti, Abdul Ajeed Mohathasim Billah, Safia Obaidur Rab, Sharuk L. Khan   +13 more
wiley   +1 more source